Novo Nordisk Launches New Semaglutide Treatment for Type 2 Diabetes in Thailand
Novo Nordisk has introduced a high-dose Semaglutide treatment in Thailand, aiming to address cardiovascular, kidney, and metabolic health in Type 2 diabetes patients.
According to Khaosod Online, Novo Nordisk Pharma (Thailand) has officially launched a new high-dose Semaglutide treatment option for patients living with Type 2 diabetes. The company emphasizes that this treatment is designed to provide holistic care, moving beyond simple blood sugar management to address the broader cardiovascular-kidney-metabolic (CKM) syndrome.
This development is significant for residents and long-term visitors in Thailand, as the prevalence of Type 2 diabetes in the country has risen to 10.6% in 2025, up from 9.5% in 2020. Novo Nordisk is advocating for a shift in public perception, framing Type 2 diabetes as a chronic, progressive, and serious condition that requires comprehensive medical attention rather than just glucose monitoring.
For those managing diabetes, this new treatment option expands the tools available to local healthcare providers. However, patients should consult with their medical professionals to determine if this specific medication is appropriate for their individual health profile. As this is a prescription-based medical advancement, details regarding specific availability at local hospitals, insurance coverage, and individual eligibility remain matters to be discussed directly with healthcare providers. Novo Nordisk continues to highlight its commitment to addressing the health challenges faced by millions of people living with diabetes in Thailand.
